Skip to main content

Galter Laboratory

We are interested in the pathological alterations in neurodegenerative diseases, in particular in Parkinson disease.

A section of the humain midbrain hybridized with a radioactive-labeled tyrosine hydroxylase (TH) - specific probe, the key enzyme for dopamine production.

Research focus

We are interested in the pathological alterations in neurodegenerative diseases, in particular in Parkinson disease. During the last decade considerable progress has been made with respect to the genetic basis of the disease. Several genetic factors have been identified that are associated with Parkinson disease, and the biological pathways leading to pathology are under intense investigation. Besides the degeneration of dopamine neurons in the midbrain and depletion of striatal dopamine levels, we know that other cells undergo pathological changes in the brain and in peripheral organs including the gut.

  1. We study genetic risk factors linked to monogenetic forms of Parkinson disease both in postmortem human patient material and model systems. Many of the mutant genes are involved in mitochondrial or lysosomal functions. In collaboration with other research groups we use rodent models carrying these mutations to explore the mechanisms leading to degeneration.
  2. We also study the development of motor and non-motor symptoms in a genetic mouse model of Parkinson disease, the MitoPark mouse. These mice, which mimic mitochondrial failure in dopamine neurons detected in Parkinson patients, develop slowly progressing motor impairments and gut disturbances. At different ages mice can be used to test novel treatment strategies for patients in early, middle and late stages of the disease. Different variants of the MitoPark line are used to study the role of glia cells in Parkinson disease.

We combine behavioral tests with biochemical and histological methods to study molecular alterations in distinct brain areas or cell populations affected in the brain and gastro-intestinal tract. A detailed understanding of pathological alterations in the central and enteric nervous system associated with Parkinson’s disease will possibly pave the way for future therapies for neurodegeneration, targeting also glia cells.

Selected publications

ADAR2 affects mRNA coding sequence edits with only modest effects on gene expression or splicing in vivo.
Dillman AA, Cookson MR, Galter D
RNA Biol 2016 ;13(1):15-24

Altered Expression of Growth Associated Protein-43 and Rho Kinase in Human Patients with Parkinson's Disease.
Saal KA, Galter D, Roeber S, Bähr M, Tönges L, Lingor P
Brain Pathol. 2017 01;27(1):13-25

Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
Gellhaar S, Marcellino D, Abrams MB, Galter D
Genes Brain Behav. 2015 Mar;14(3):260-70

Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.
Tsika E, Kannan M, Foo CS, Dikeman D, Glauser L, Gellhaar S, et al
Neurobiol. Dis. 2014 Nov;71():345-58

mRNA expression, splicing and editing in the embryonic and adult mouse cerebral cortex.
Dillman AA, Hauser DN, Gibbs JR, Nalls MA, McCoy MK, Rudenko IN, et al
Nat. Neurosci. 2013 Apr;16(4):499-506


Dagmar Galter

Senior researcher
08-524 870 18
CC Comparative Medicine